- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Expert Discusses Chinese Biosimilar Business Prospects in the European Union
A consultant who specializes in helping Chinese biosimilar companies market their products in the European Union discusses the challenges and opportunities.
Jenny Hao, pharma operating partner with Convergence Partners, is a biosimilars consultant who spoke recently at the Terrapinn Festival of Biologics meeting in Basel, Switzerland. In this video, she speaks with Tony Hagen, senior editor for The Center for Biosimilars® about the interest Chinese biosimilars producers have in Europe and the challenges they face. The prospects for biosimilar sales in China are huge, but there are many companies in the market battling for share, and so they are slowly turning in the direction of sales abroad, including the European Union, she explains. However, in entering the European Union they must go up against many large and well-established biopharmaceutical companies. Ultimately, market share will go to the most efficient and economical producers, Hao says.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
